Targeted delivery system
The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle.
1. A treatment delivery platform, comprising:
a polypeptide sequence adapted to target and penetrate a cancer cell, wherein the polypeptide sequence comprises, from N-terminus to C-terminus, a Her segment, a penton base segment, and a decalysine motif, and
a delivery molecule bound to the decalysine motif via electrostatic interactions, wherein the delivery molecule comprises a triphosphate-capped siRNA.
2. The treatment delivery platform of claim 1 , wherein the polypeptide sequence comprises SEQ ID NO:5.
3. The treatment delivery platform of claim 1 , wherein the siRNA comprises a T7 transcribed siRNA.
4. The treatment delivery platform of claim 1 , wherein the siRNA is a HER2 siRNA.
5. The treatment delivery platform of claim 1 , wherein the polypeptide sequence comprises a sequence encoded by SEQ ID NO:1.
6. The treatment delivery platform of claim 1 , wherein the penton base segment is an adenovirus serotype 5 (Ad5) penton base segment.
7. The treatment delivery platform of claim 1 , wherein the cancer cell is a HER2+ cancer cell.
8. The treatment delivery platform of claim 1 , wherein the cancer cell is a breast cancer cell.
9. A pharmaceutical composition, comprising:
a treatment delivery platform, comprising:
a polypeptide sequence adapted to target and penetrate a cancer cell, wherein the polypeptide sequence comprises, from N-terminus to C-terminus, a Her segment, a penton base segment, and a decalysine motif, and
a delivery molecule bound to the decalysine motif via electrostatic interactions, wherein the delivery molecule comprises a triphosphate-capped siRNA; and
a pharmaceutically acceptable carrier.
10. The pharmaceutical composition of claim 9 , wherein the polypeptide sequence comprises a sequence encoded by SEQ ID NO:1.
11. The pharmaceutical composition of claim 9 , wherein the siRNA comprises a T7-transcribed siRNA.
12. The pharmaceutical composition of claim 9 , wherein the siRNA is a HER2 siRNA.
13. The pharmaceutical composition of claim 9 , wherein the polypeptide sequence comprises SEQ ID NO: 5.
14. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated for parenteral administration.
15. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is a lyophilized powder.
16. The pharmaceutical composition of claim 9 , wherein the penton base segment is an adenovirus serotype 5 (Ad5) penton base segment.
17. The pharmaceutical composition of claim 9 , wherein the cancer cell is a HER2+ cancer cell.
18. The pharmaceutical composition of claim 9 , wherein the cancer cell is a breast cancer cell.